HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Smith, M. L. Articles by Bessent, R. G. Search for Related Content PubMed PubMed Citation Articles by Smith, M. L. Articles by Bessent, R. G.

Relative Distribution of Diphosphonate Between Bone and Soft Tissue at 4 and 24 Hours: Concise Communication

Royal Infirmary, and Department of Clinical Physics and Bio-Engineering, Glasgow, Scotland

Correspondence: For reprints contact: Marie L. Smith, Royal Infirmary and Dept. of Clinical Physics and Bio-Engineering, Glasgow, G4 OSF, Scotland.

ABSTRACT

Digital bone scintigrams were obtained in 19 patients using Tc-99m hydroxy-ethylidene diphosphonate (HEDP), These were quantitated for skeletal, soft-tissue and renal uptake of tracer using a contrast-enhancement technique to define the regions of interest. Twenty-four hr whole-body retention (WBR)of HEDP was also measured. It was found that approximately 70% of retained diphosphonate was localized in the skeleton at 24 hr, with 26% in soft tissue and 4% in kidneys. However, we have shown that over a wide spectrum of whole-body retention measurements (18 to 70%) the 24-hr soft-tissue component, as a percentage of administered dose, remained relatively constant whereas skeletal tracer accumulation mirrored WBR (r = 0.98, p <0.001). The present study indicates that, despite a significant but essentially stable soft-tissue component, measurement of 24-hr WBR of HEDP accurately reflects skeletal metabolism.

This article has been cited by other articles:

				W. Brenner, W. U. Kampen, A. M. Kampen, and E. Henze Skeletal Uptake and Soft-Tissue Retention of 186Re-HEDP and 153Sm-EDTMP in Patients with Metastatic Bone Disease J. Nucl. Med., February 1, 2001; 42(2): 230 - 236. [Abstract] [Full Text]